AN
About
Angion Biomedica is a clinical-stage organ restoration biopharmaceutical company focused on renal disease. Its investigational drug BB3 is entering phase 3 for delayed graft function following kidney transplant and phase 2 for acute kidney injury following open-heart surgery using cardiopulmonary bypass.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 3 investors are based in Uniondale, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Uniondale, US
Contact Information
Find more investors like Angion
Search Investors